People | December 14, 2023
Moderna Chief Commercial Officer steps down, President to look over pipeline strategy
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Announces changes to commercial organization to prepare for multiple product launches in 2024 and 2025
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
Decision on EU marketing authorisation expected for momelotinib by early 2024
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
Yesafili, received marketing authorization approval from the European Commission for the European Union
he company posted total income during Q2 FY24 at Rs. 12.86 crore
Subscribe To Our Newsletter & Stay Updated
